OBJECTIVE: To investigate risk factors in subclinical atherosclerosis progression as measured by coronary artery calcium (CAC) and aorta calcium (AC) in women with systemic lupus erythematosus (SLE; cases) and in comparison with a control population. METHODS: A cohort of 149 cases and 124 controls participated in the Study of Lupus Vascular and Bone Long-Term Endpoints. Demographic information, cardiovascular and SLE risk factors, and laboratory assessments were collected at an initial visit. CAC and AC were measured by electron beam computed tomography (CT) or multidetector CT at an initial visit and at a followup visit. Logistic regression models were used to identify predictors of progression in CAC and AC; multivariate models were adjusted for age, hypertension, and total cholesterol to high-density lipoprotein ratio. RESULTS: Higher modified Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) score (odds ratio [OR] 2.15, 95% confidence interval [95% CI] 1.33-3.57), use of a corticosteroid (OR 2.93, 95% CI 1.14-7.86), and use of aspirin (OR 4.23, 95% CI 1.53-11.74) were associated with CAC progression in multivariate models. Presence of SLE (OR 2.64, 95% CI 1.26-5.72), lower C3 (OR 0.54, 95% CI 0.33-0.87), lower C4 (OR 0.49, 95% CI 0.27-0.86), use of a corticosteroid (OR 2.73, 95% CI 1.03-7.64), higher corticosteroid dose (OR 1.77, 95% CI 1.12-3.00), higher lipoprotein(a) (OR 1.80, 95% CI 1.11-2.98), and higher homocysteine (OR 2.06, 95% CI 1.06-4.29) were associated with AC progression in multivariate models. CONCLUSION: Higher disease damage at the first study visit, as measured by the modified SDI, may predict increased risk in CAC progression, whereas higher disease activity at the first study visit, as measured by hypocomplementemia and use of corticosteroids, may predict increased risk in AC progression.
OBJECTIVE: To investigate risk factors in subclinical atherosclerosis progression as measured by coronary artery calcium (CAC) and aorta calcium (AC) in women with systemic lupus erythematosus (SLE; cases) and in comparison with a control population. METHODS: A cohort of 149 cases and 124 controls participated in the Study of Lupus Vascular and Bone Long-Term Endpoints. Demographic information, cardiovascular and SLE risk factors, and laboratory assessments were collected at an initial visit. CAC and AC were measured by electron beam computed tomography (CT) or multidetector CT at an initial visit and at a followup visit. Logistic regression models were used to identify predictors of progression in CAC and AC; multivariate models were adjusted for age, hypertension, and total cholesterol to high-density lipoprotein ratio. RESULTS: Higher modified Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) score (odds ratio [OR] 2.15, 95% confidence interval [95% CI] 1.33-3.57), use of a corticosteroid (OR 2.93, 95% CI 1.14-7.86), and use of aspirin (OR 4.23, 95% CI 1.53-11.74) were associated with CAC progression in multivariate models. Presence of SLE (OR 2.64, 95% CI 1.26-5.72), lower C3 (OR 0.54, 95% CI 0.33-0.87), lower C4 (OR 0.49, 95% CI 0.27-0.86), use of a corticosteroid (OR 2.73, 95% CI 1.03-7.64), higher corticosteroid dose (OR 1.77, 95% CI 1.12-3.00), higher lipoprotein(a) (OR 1.80, 95% CI 1.11-2.98), and higher homocysteine (OR 2.06, 95% CI 1.06-4.29) were associated with AC progression in multivariate models. CONCLUSION: Higher disease damage at the first study visit, as measured by the modified SDI, may predict increased risk in CAC progression, whereas higher disease activity at the first study visit, as measured by hypocomplementemia and use of corticosteroids, may predict increased risk in AC progression.
Authors: Joan M Von Feldt; Lisabeth V Scalzi; Andrew J Cucchiara; Suneetha Morthala; Carmel Kealey; Stephanie D Flagg; Anna Genin; Alison L Van Dyke; Eleni Nackos; Avantika Chander; Erika Gehrie; Randy Q Cron; Alexander S Whitehead Journal: Arthritis Rheum Date: 2006-07
Authors: Robert C Detrano; Melissa Anderson; Jennifer Nelson; Nathan D Wong; J Jeffrey Carr; Michael McNitt-Gray; Diane E Bild Journal: Radiology Date: 2005-06-21 Impact factor: 11.105
Authors: Sekar Kathiresan; Martin G Larson; Michelle J Keyes; Joseph F Polak; Philip A Wolf; Ralph B D'Agostino; Farouc A Jaffer; Melvin E Clouse; Daniel Levy; Warren J Manning; Christopher J O'Donnell Journal: Am J Cardiol Date: 2006-12-14 Impact factor: 2.778
Authors: Ann Van Campenhout; Corey S Moran; Adam Parr; Paula Clancy; Catherine Rush; Hieronim Jakubowski; Jonathan Golledge Journal: Atherosclerosis Date: 2008-05-28 Impact factor: 5.162
Authors: Jarett D Berry; Kiang Liu; Aaron R Folsom; Cora E Lewis; J Jeffrey Carr; Joseph F Polak; Steven Shea; Stephen Sidney; Daniel H O'Leary; Cheeling Chan; Donald M Lloyd-Jones Journal: Circulation Date: 2009-01-12 Impact factor: 29.690
Authors: Mary J Roman; Mary K Crow; Michael D Lockshin; Richard B Devereux; Stephen A Paget; Lisa Sammaritano; Daniel M Levine; Adrienne Davis; Jane E Salmon Journal: Arthritis Rheum Date: 2007-10
Authors: Trina Thompson; Kim Sutton-Tyrrell; Rachel P Wildman; Amy Kao; Shirley G Fitzgerald; Betsy Shook; Russell P Tracy; Lewis H Kuller; Sarah Brockwell; Susan Manzi Journal: Arthritis Rheum Date: 2008-03
Authors: April Jorge; Apinya Lertratanakul; Jungwha Lee; William Pearce; David McPherson; Trina Thompson; Emma Barinas-Mitchell; Rosalind Ramsey-Goldman Journal: Arthritis Care Res (Hoboken) Date: 2016-11-21 Impact factor: 4.794
Authors: Abdulla Watad; Arsalan Abu Much; Danielle Bracco; Naim Mahroum; Doron Comaneshter; Arnon D Cohen; Howard Amital Journal: Immunol Res Date: 2017-04 Impact factor: 2.829
Authors: Paola C Roldan; Ernest R Greene; Clifford R Qualls; Wilmer L Sibbitt; Carlos A Roldan Journal: Rheumatol Int Date: 2019-03-16 Impact factor: 2.631
Authors: Sofia Ajeganova; Thomas Gustafsson; Tomas Jogestrand; Johan Frostegård; Ingiäld Hafström Journal: Arthritis Res Ther Date: 2015-03-25 Impact factor: 5.156